Liposomes in the Treatment of Parasitic, Viral, Fungal and Bacterial Infections

References

• Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1113: 171
   PubMed Web of Science ®Google Scholar
• O'Reilly T., Zak O. Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin. Infect. Dis. 1992; 14: 1100
   Google Scholar
• Vogels M. T.E., Van der Meer J. W.M. Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob. Agents Chemother. 1992; 36: 1
   PubMed Web of Science ®Google Scholar
• Hockertz S., Franke G., Paulini I., Lohmann-Matthes M. L. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-γ and MTPPE encapsulated in liposomes. J. Interferon Res. 1991; 11: 177
   PubMedGoogle Scholar
• Koff W. C., Fidler I. J. The potential use of liposome-mediated antiviral therapy. Antiviral Res. 1985; 5: 179
   PubMed Web of Science ®Google Scholar
• Dukor P., Schumann G. Modulation of non-specific resistance by MTPPE. Immunopharmacology of infectious diseases. Vaccine adjuvants and modulators of non-specific resistance of infectious diseases, J. A. Majde. Alan R Liss Inc., New York 1987; 255
   Google Scholar
• Gangemi J. D., Nachtigal M., Barnhart D., Krech L., Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J. Infect. Dis. 1987; 155: 510
   PubMed Web of Science ®Google Scholar
• Koff W. C., Showalter S. D., Hampar B., Fidler I. J. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Science 1985; 228: 495
   PubMed Web of Science ®Google Scholar
• Eppstein D. A., Van der Pas M.A., Fraser-Smith E. B., et al. Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int. J. Immunother. 1986; 2: 115
   Web of Science ®Google Scholar
• Bakker-Woudenberg I. A.J.M., Lokerse A. F., Vink-van den Berg J. C., Roerdink F. M. Effect of free or liposome-encapsulated MDP on the uptake and intracellular survival of Listeria monocytogenes, in peritoneal mouse macrophages in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 1989; 8: 603
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Chedid L. Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice. Infect. Immun. 1987; 55: 1426
   PubMed Web of Science ®Google Scholar
• Izbicki J. R., Raedler C., Anke A., et al. Beneficial effect of liposomeencapsulated muramyl tripeptide in experimental septicemia in a porcine model. Infect. Immun. 1991; 59: 126
   PubMed Web of Science ®Google Scholar
• Mellors J. W., Debs R. J., Ryan J. L. Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity. Infect. Immun. 1989; 57: 132
   PubMed Web of Science ®Google Scholar
• Eppstein D. A., Van der Pas M. A., Gloff C. A., Soike K. F. Liposomal interferon-ß: sustained release treatment of simian varicella virus infection in monkeys. J. Infect. Dis. 1989; 159: 616
   PubMed Web of Science ®Google Scholar
• Melissen P. M.B., Van Vianen W., Van Marion M., Bakker-Woudenberg I. A.J.M. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-γ (IFN-γ) in experimental infection with Listeria monocytogenes. Biotherapy 1993; 6: 113
   PubMedGoogle Scholar
• Lazdins J. K., Walker M., Alteri E. The lipophilic muramyl peptide MTPPE is a potent inhibitor of HIV replication in macrophages. AIDS Res. Hum. Retroviruses 1990; 6: 1157
   PubMed Web of Science ®Google Scholar
• Melissen P. M.B., Van Vianen W., Rijsbergen Y., Bakker-Woudenberg I. A.J.M. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae. infection. Infect. Immun. 1992; 60: 95
   PubMed Web of Science ®Google Scholar
• Melissen P. M.B., Van Vianen W., Bakker-Woudenberg I. A.J.M. Treatment of Klebsiella pneumoniae, septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphaltidylethanolamide (MTPPE). Antimicrob. Agents Chemother. 1994; 38: 147
   PubMed Web of Science ®Google Scholar
• Alving C. R., Steck E. A., Chapman W. L., et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. U.S.A. 1978; 75: 2959
   PubMed Web of Science ®Google Scholar
• New R. R.C., Chance M. L., Thomas S. C., Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature 1978; 272: 55
   PubMed Web of Science ®Google Scholar
• New R. R.C., Chance M. L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 1981; 8: 371
   PubMed Web of Science ®Google Scholar
• Berman J. D., Hanson W. L., Chapman W. L., Alving C. R., Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 1986; 30: 847
   PubMed Web of Science ®Google Scholar
• Berman J. D., Ksionski G., Chapman W. L., Waits V. B., Hanson W. L. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 1992; 36: 1978
   PubMed Web of Science ®Google Scholar
• Croft S. L., Davidson R. N., Thornton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Chemother. 1991; 28(Suppl. B)111
   PubMed Web of Science ®Google Scholar
• Croft S. L. Liposomes in the treatment of parasitic diseases. Pharmacy International 1986; 7: 229
   Google Scholar
• Alving C. R., Weldon J. S., Munnell J. F., Hanson W. L. Liposomes in leishmaniasis:the lysosome connection. Receptor-mediated targeting of drugs, G. Gregoriadis, G. Poste, J. Senior, A. Trouet. NATO ASI Series, Plenum Press, New York 1985; 317
   Google Scholar
• Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D.M. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991; 337: 1061
   PubMed Web of Science ®Google Scholar
• Lazanas M. C., Tsekes G. A., Papandreous S., et al. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993; 7: 1018
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros J., Villanueva J. L., Kindelan J. M., Jurado R., Sanchez-Guijo P. Succesful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 1993; 17: 625
   PubMed Web of Science ®Google Scholar
• Peeters P. A.M., Huiskamp C. W.E.M., Eling W. M.C., Crommelin D. J.A. Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology 1989; 98: 381
   PubMed Web of Science ®Google Scholar
• Pirson P., Steiger R. F., Trouer A., Gillet J., Herman F. Primaquine liposomes in the chemotherapy of experimental murine malaria. Ann. Trop. Med. Parasitol. 1980; 74: 383
   PubMed Web of Science ®Google Scholar
• Chandra S., Agrawal A. K., Gupta C. M. Chloroquine delivery to erythrocytes in Plasmodium berghei, infected mice using antibody-bearing liposomes as drug vehicles. J. Biosci. 1991; 16: 137
   Web of Science ®Google Scholar
• Kende M., Alving C. R., Rill W. L., Swartz G. M., Canonico P. G. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 1985; 27: 903
   PubMed Web of Science ®Google Scholar
• Chu C. J., Szoka F. C. Antiviral activity and pharmacokinetics of liposome-encapsulated phosphonoformate in Rauscher murine leukemia virus-infected mice. J. Liposome Res. 1992; 2: 67
   Google Scholar
• Phillips N. C. Liposomal carriers for the treatment of acquired immune deficiency syndromes. Bull. Inst. Pasteur 1992; 90: 205
   Google Scholar
• Phillips N. C., Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992; 79: 1137
   PubMed Web of Science ®Google Scholar
• Szoka F. C., Chu C. J. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Antimicrob. Agents Chemother. 1988; 32: 858
   PubMed Web of Science ®Google Scholar
• Wyde P. R., Six H. R., Wilson S. Z., Gilbert B. E., Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob. Agents Chemother. 1988; 32: 890
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wahl S. M., Betageri G. V., et al. Inhibition of HIV-1 in monocyte/macrophage cultures by 2′, 3′ – dideoxycytidine -5′-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 1990; 6: 691
   PubMed Web of Science ®Google Scholar
• Gümbel H. O.C., Rückert D. G., Cinatl J., Rabenau H., Doerr H. W., Ohrloff C. in vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet. German J. Ophthalmol. 1994; 3: 5
   Google Scholar
• Norley S. G., Huang L., Rouse B. T. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J. Immunol. 1986; 136: 681
   PubMedGoogle Scholar
• Compagnon B., Milhaud P., Bienvenue A., Philippot J. R. Targeting of Poly(rl)-Poly(rC) by fusogenic (F protein) immunoliposomes. Exp. Cell. Res. 1992; 200: 333
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Grant C. W.M., Barber K. R., Kalp M. A. Mechanisms of the selective toxicity of amphotericin B incorporated into liposomes. Molec. Pharmacol. 1987; 31: 1
   PubMed Web of Science ®Google Scholar
• Patterson T. F., Andrioli V. T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur. J. Cancer Clin Oncol. 1989; 25(Suppl. 2)S63
   Google Scholar
• Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B delivery systems. Antimicrob. Agents Chemother. 1990; 34: 381
   PubMed Web of Science ®Google Scholar
• Gates C., Pinney R. J. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Pharm. Ther. 1993; 18: 147
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Mehta R., Hopfer R. L., et al. Treatment and prophylaxis of disseminated infection due to Candida albicans, in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 1983; 147: 939
   PubMed Web of Science ®Google Scholar
• Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome associated amphotericin B. J. Infect. Dis. 1982; 145: 748
   PubMed Web of Science ®Google Scholar
• Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes:a novel therapy for histoplasmosis. Am. Rev. Respir. Dis. 1982; 125: 610
   PubMedGoogle Scholar
• Lopez-Berestein G., Hopfer R. L., Mehta R., Mehta K., Hersh E. M., Juliano R. L. Liposome-encapsulated amphotericin B for treatment of disseminated Candidiasis in neutropenic mice. J. Infect. Dis. 1984; 150: 278
   PubMed Web of Science ®Google Scholar
• Clark J. M., Whitney R. R., Olsen S. J., George R. J., Swerdel M. R., Kuuselman L., Bonner D. P. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 1992; 35: 615
   Google Scholar
• Clemons K. V., Stevens D. A. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 1992; 30: 353
   PubMed Web of Science ®Google Scholar
• Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 1989; 33: 1544
   PubMed Web of Science ®Google Scholar
• Adler-Moore J. P., Chiang S. M., Satorius A., et al. Treatment of murine candidosis and cryptococcosis with unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother 1991; 28(Suppl. B)63
   PubMed Web of Science ®Google Scholar
• Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Ryan J. L., Andrioli V. T. Treatment of experimental invasive Aspergillosis with novel amphotericin B/Cholesterol-Sulfate complexes. J. Infect Dis 1989; 159: 717
   PubMed Web of Science ®Google Scholar
• Clemons K. V., Stevens D. A. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. 1991; 35: 1829
   PubMed Web of Science ®Google Scholar
• Hostetler J. S., Clemons K. V., Hanson L. H., Stevens D. A. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 1992; 36: 2656
   PubMed Web of Science ®Google Scholar
• Van Etten E. W.M., Van den Heuvel-de Groot C., Bakker-Woudenberg I. A.J.M. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome), and Fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. J. Antimicrob. Chemother. 1993; 32: 723
   PubMed Web of Science ®Google Scholar
• Clemons K. V., Stevens D. A. Therapeutic efficacy of liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 1993; 32: 465
   PubMed Web of Science ®Google Scholar
• Hospenthal D. R., Rogers A. L., Beneke E. S. Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob. Agents Chemother. 1989; 33: 16
   PubMedGoogle Scholar
• Belay T., Hospenthal D. R., Rogers A. L., Patterson M. J. Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model. J. Med. Vet. Mycol. 1991; 29: 419
   PubMedGoogle Scholar
• De Marie S., Janknegt R., Bakker-Woudenberg I. A.J.M. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 1994; 33: 907
   PubMedGoogle Scholar
• Lopez-Berestein G., Fainstein V., Hopfer R., et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer:a preliminary study. J. Infect. Dis. 1985; 151: 704
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Bodey G. P., Fainstein V., et al. Treatment of systemic fungal infections. Arch. Intern. Med. 1989; 149: 2533
   PubMed Web of Science ®Google Scholar
• Sculier J. P., Coune A., Meunier F., et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur. J. Cancer Clin. Oncol. 1988; 24: 527
   PubMedGoogle Scholar
• Sculier J. P., Klastersky J., Libert P., et al. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. Eur. J. Cancer 1990; 26: 919
   PubMed Web of Science ®Google Scholar
• Chopra R., Blair S., Strang J., Cervi P., Patterson K. G., Goldstone A. H. Liposomal amphotericin B (AmBisome) in treatment of fungal infections in neutropenic patients. J. Antimicrob. Chemother. 1991; 28(Suppl. B)93
   PubMedGoogle Scholar
• Ringdén O., Meunier F., Tollemar J., et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 1991; 28(Suppl B)73
   PubMed Web of Science ®Google Scholar
• Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (A-mBisome):safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 1991; 28(Suppl B)83
   PubMedGoogle Scholar
• Chopra R., Fielding A., Goldstone A. H. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin B (AmBisome) – A report on 40 cases from a single centre. Leukemia and Lymphoma 1992; 7(Suppl)73
   PubMedGoogle Scholar
• Coker R. J., Viviani M., Gazzard B. G., Du Pont B., Pohle M. D., Murphy S. M. Treatment of cryptococcosis with liposomal amphotericin B (A-mBisome) in 23 patients with AIDS. AIDS 1993; 7: 829
   PubMed Web of Science ®Google Scholar
• Janknegt R., De Marie S., Bakker-Woudenberg I. A.J.M., Crommelin D. J.A. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokinet. 1992; 23: 279
   PubMed Web of Science ®Google Scholar
• Tollemar J., Ringdén O., Tydén G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin. Transpl. 1990; 4: 167
   Web of Science ®Google Scholar
• Schürmann D., De Matos Marques B., Grünewald T., Pohle H. D., Hahn H., Ruf B. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J. Infect. Dis. 1991; 164: 620
   PubMed Web of Science ®Google Scholar
• Kan V. L., Bennett J. E., Amantea M. A., et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. 1991; 164: 418
   PubMed Web of Science ®Google Scholar
• Sanders S. W., Buchi K. N., Goddard M. S., Lang J. K., Tolman K. G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 1991; 35: 1029
   PubMed Web of Science ®Google Scholar
• Karlowsky J. A., Zhanel G. G. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin. Infect. Dis. 1992; 15: 654
   PubMed Web of Science ®Google Scholar
• Vladimirsky M. A., Ladigina G. A. Antibacterial activity of liposome-encapsulated streptomycin in mice infected with Mycobacterium tuberculosis. Biomedicine 1982; 36: 375
   Google Scholar
• Orozco L. C., Quintana F. O., Beltrán R. M., De Moreno I., Wasserman M., Rodriguez G. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Tubercle 1986; 67: 91
   PubMedGoogle Scholar
• Ladigina G. A., Vladimirsky M. A. The comparative pharmacokinetics of 3H-dihydrostreptomycin in solution and liposomal form in normal and Mycobacterium tuberculosis infected mice. Biomed. Pharmacother. 1986; 40: 416
   PubMed Web of Science ®Google Scholar
• Desiderio J. V., Campbell S. G. Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis. J. Reticuloendoth. Soc. 1983; 34: 279
   PubMedGoogle Scholar
• Tadakuma T., Ikewaki N., Yasude T., Tsutsumi M., Saito S., Saito K. Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes. Antimicrob. Agents Chemother. 1985; 28: 28
   PubMed Web of Science ®Google Scholar
• Swenson C. E., Stewart K. A., Hammett J. L., Fitzsimmons W. E., Ginsberg R. S. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob. Agents Chemother. 1990; 34: 235
   PubMed Web of Science ®Google Scholar
• Fierer J., Hatlen J., Liu J. P., Estrella D., Mihalko P., Yau-Young A. Successful treatment using gentamicin liposomes of Salmonella dublin, infections in mice. Antimicrob. Agents Chemother. 1990; 34: 343
   PubMed Web of Science ®Google Scholar
• Fattal E., Rojas J., Youssef M., Couvreur P., Andremont A. Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob. Agents Chemother. 1991; 35: 770
   PubMed Web of Science ®Google Scholar
• Magallanes M., Dijkstra J., Fierer J. Liposome- incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob. Agents Chemother. 1993; 37: 2293
   PubMed Web of Science ®Google Scholar
• Dees C., Fountain M. W., Taylor J. R., Schultz R. D. Enhanced intraphagocytic killing of Brucella abortus, in bovine mononuclear cells by liposomes containing gentamicin. Vet. Immunol. Immunopathol. 1985; 8: 171
   PubMed Web of Science ®Google Scholar
• Fountain M. W., Weiss S. J., Fountain A. G., Shen A., Lenk R. P. Treatment of Brucella canis, and Brucella abortus, in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J. Infect. Dis. 1985; 152: 529
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A.J.M., Lokerse A. F., Roerdink F. H., Regts D., Michel M. F. Free versus liposome-entrapped ampicillin in treatment of infection due to Listeria monocytogenes, in normal and athymic (nude) mice. J. Infect. Dis. 1985; 151: 917
   PubMed Web of Science ®Google Scholar
• Düzgünes N., Perumal V. K., Kesavalu L., Goldstein J. A., Debs R. J., Gangadharam P. R.J. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare, complex infection in beige mice. Antimicrob. Agents Chemother. 1988; 32: 1404
   PubMed Web of Science ®Google Scholar
• Saito H., Tomioka H. Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium, complex infection induced in mice. Antimicrob. Agents Chemother. 1989; 33: 429
   PubMed Web of Science ®Google Scholar
• Cynamon M. H., Swenson C. E., Palmer G. S., Ginsberg R. S. Liposome-encapsulated-amikacin therapy of Mycobacterium avium, complex infection in beige mice. Antimicrob. Agents Chemother. 1989; 33: 1179
   PubMed Web of Science ®Google Scholar
• Bermudez L. E., Yau-Young A. O., Lin J. P., Cogger J., Young L. S. Treatment of disseminated Mycobacterium avium, complex infection of beige mice with liposome-encapsulated aminoglycosides. J. Infect. Dis. 1990; 161: 1262
   PubMed Web of Science ®Google Scholar
• Klemens S. P., Cynamon M. H., Swenson C. E., Ginsberg R. S. Liposome-encapsulated gentamicin therapy of Mycobacterium avium, complex infection in beige mice. Antimicrob. Agents Chemother. 1990; 34: 967
   PubMed Web of Science ®Google Scholar
• Gangadharam P. R.J., Ashtekar D. A., Ghori N., Goldstein J. A., Debs R. J., Düzgünes N. Chemotherapeutic potential of free and liposome-encapsulated streptomycin against experimental Mycobacterium avium, complex infections in beige mice. J. Antimicrob. Chemother. 1991; 28: 425
   PubMed Web of Science ®Google Scholar
• Tomioka H., Saito H., Sato K., Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare, infection induced in mice. Am. Rev. Respir. Dis. 1991; 144: 575
   PubMedGoogle Scholar
• Düzgünes N., Ashtekar D. R., Flasher D. L., et al. Treatment of Mycobacterium avium-intracellulare, complex infection in beige mice with free and liposome-encapsulated streptomycin:role of liposome type and duration of treatment. J. Infect. Dis. 1991; 164: 143
   PubMed Web of Science ®Google Scholar
• Nightingale S. D., Saletan S. L., Swenson C. E., et al. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare, complex bacteremia in AIDS patients. Antimicrob. Agents Chemother. 1993; 37: 1869
   PubMed Web of Science ®Google Scholar
• Sunamoto J., Goto M., Iida T., Hara K., Saito A., Tomonaga A. Unexpected tissue distribution of liposomes coated with amylopectin derivatives and successful use in the treatment of experimental Legionnaires' disease. Receptor-mediated targeting of drugs, G. Gregoriadis, G. Poste, J. Senior, A. Trouet. NATO ASI Series, Plenum Press, New York 1985; 359
   Google Scholar
• Bonventre P. F., Gregoriadis G. Killing of intraphagocytic Staphylococcus aureus, by dihydrostreptomycin entrapped within liposomes. Antimicrob. Agents Chemother. 1978; 13: 1049
   PubMed Web of Science ®Google Scholar
• Fountain M. W., Dees C., Schultz R. D. Enhanced intracellular killing of Staphylococcus aureus, by canine monocytes treated with liposomes containing amikacin, gentamicin, kanamycin and tobramycin. Curr. Microbiol. 1981; 6: 373
   Google Scholar
• MacLeod D. L., Prescott J. F. The use of liposomally-entrapped gentamicin in the treatment of bovine Staphylococcus aureus, mastitis. Can. J. Vet. Res. 1988; 52: 445
   Google Scholar
• Dees C., Schultz R. D. The mechanism of enhanced intraphagocytic killing of bacteria by liposomes containing antibiotics. Vet. Immunol. Immunopathol. 1990; 24: 135
   PubMed Web of Science ®Google Scholar
• Desiderio J. V., Campbell S. G. Intraphagocytic killing of Salmonella typhimurium, by liposome-encapsulated cephalothin. J. Infect. Dis. 1983; 148: 563
   PubMed Web of Science ®Google Scholar
• Stevenson M., Baillie A. J., Richards R. M.E. Enhanced activity of streptomycin and chlooramphenicol against intracellular Escherichia coli, in the J774 macrophage cell line mediated by liposome delivery. Antimicrob. Agents Chemother. 1983; 24: 742
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A.J.M., Lokerse A. F., Roerdink F. H. Antibacterial activity of liposome-entrapped ampicillin in vitro and in vivo in relation to the lipid composition. J. Pharmacol. Exp. Ther. 1989; 251: 321
   PubMed Web of Science ®Google Scholar
• Forestier F., Gerrier P., Chaumard C., Quero A. M., Couvreur P., Labarre C. Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes, in mouse peritoneal macrophages. J. Antimicrob. Chemother. 1992; 30: 173
   PubMed Web of Science ®Google Scholar
• Al-Awadhi H., Stokes G. V., Reich M. Inhibition of Chlamydia trachomatis, growth in mouse fibroblasts by liposome-encapsulated tetracyline. J. Antimicrob. Chemother. 1992; 30: 303
   PubMed Web of Science ®Google Scholar
• Jansons V. K., Soggin A. Clofazimine and liposomes enhance the susceptibility of intracellular Mycobacterium avium, towards rifabutin. Curr. Microbiol. 1990; 20: 261
   Google Scholar
• Kesavalu L., Goldstein J. A., Debs R. J., Düzgünes N., Gangadharam P. R.J. Differential effects of free and liposome-encapsulated amikacin on the survival of Mycobacterium avium, complex in mouse peritoneal macrophages. Tubercle 1990; 71: 215
   PubMedGoogle Scholar
• Ashtekar D., Düzgünes N., Gangadharam P. R.J. Activity of free and liposome-encapsulated streptomycin against Mycobacterium avium, complex (MAC) inside peritoneal macrophages. J. Antimicrob. Chemother. 1991; 28: 615
   PubMed Web of Science ®Google Scholar
• Bermudez L. E.M., Wu M., Young L. S. Intracellular killing of Mycobacterium avium, complex by rifapentine and liposome-encapsulated amikacin. J. Infect. Dis. 1987; 156: 510
   PubMed Web of Science ®Google Scholar
• Majumdar S., Flasher D., Friend D. S., et al. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare, complex infections in human peripheral blood monocyte/macrophages. Antimicrob. Agents Chemother. 1992; 36: 2808
   PubMed Web of Science ®Google Scholar
• Roesler J., Hockertz S., Vogt S., Lohmann-Matthes M. L. Staphylococci surviving intracellularly in phagocytes from patients suffering from chronic granulomatous disease are killed in vitro by antibiotics encapsulated in liposomes. J. Clin. Invest 1991; 88: 1224
   PubMed Web of Science ®Google Scholar
• Di Rocco P. H., Nacucchio M. C., Sordelli D. O., Mancuso F., Hooke A. M. The effect of liposomal cefoperazone against Pseudomonas aeruginosa, in a granulocytopenic mouse model of acute lung infection. Infection 1992; 20: 360
   PubMedGoogle Scholar
• Hwang K. J., Juen-Fai S. L., Beaumier P. L. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc. Natl. Acad. Sci. U.S.A. 1980; 77: 4030
   PubMed Web of Science ®Google Scholar
• Allen T. M., Everest J. M. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther. 1983; 226: 539
   PubMed Web of Science ®Google Scholar
• Senior J. H. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 1987; 3: 123
   PubMed Web of Science ®Google Scholar
• Allen T. M. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim. Biophys. Acta 1981; 640: 385
   PubMed Web of Science ®Google Scholar
• Senior J., Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 1982; 30: 2123
   PubMed Web of Science ®Google Scholar
• Hwang K. J., Padki M. M., Choro D. D., Essien H. E., Lai J. Y., Beaumier P. L. Uptake of small liposomes by non-reticuloendothelial tissues. Biochim. Biophys. Acta 1987; 901: 88
   PubMed Web of Science ®Google Scholar
• Allen T. M. Stealth liposomes: five years on. J. Liposome Res. 1992; 2: 289
   Google Scholar
• Wasseff N. M., Matyas G. R., Alving C. R. Complement-dependent phagocytosis of liposomes by macrophages: suppressive effects of “stealth” lipids. Biochim. Biophys. Res. Comm. 1991; 176: 866
   PubMed Web of Science ®Google Scholar
• Allen T. M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223: 42
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D., Gabizon A. Targeting of liposomes to tumor cells in vivo. Ann. N.Y. Acad. Sci. 1987; 507: 64
   PubMed Web of Science ®Google Scholar
• Allen T. M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 1989; 981: 27
   PubMed Web of Science ®Google Scholar
• Allen T. M., Ryan J. L., Papahadjopoulos D. Gangliosides reduce leakage of aqueous-space markers from liposomes in the presence of human plasma. Biochim. Biophys. Acta 1985; 818: 205
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992; 1103: 94
   PubMed Web of Science ®Google Scholar
• Allen T. M. Stealth liposomes: avoiding reticuloendothelial uptake. Liposomes in the Therapy of Infectious Diseases and Cancer, New Series, 89, G. Lopez-Berestein, I. Fidler. Alan R Liss Inc., New York, NY 1989; 405
   Google Scholar
• Gabizon A., Price D. C., Huberty J., Bresalier R. S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990; 50: 6371
   PubMed Web of Science ®Google Scholar
• Huang S. K., Mayhew E., Gilani S., Lasic D. D., Martin F. J., Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992; 52: 6774
   PubMed Web of Science ®Google Scholar
• Klibanov A. L., Huang L. Long-circulating liposomes: development and perspectives. J. Liposome Res. 1992; 2: 321
   Google Scholar
• Allen T. M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991; 1066: 29
   PubMed Web of Science ®Google Scholar
• Klibanov A. L., Maruyama K., Beckerleg A. M., Torchillin V. P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1991; 1062: 142
   PubMed Web of Science ®Google Scholar
• Woodle M. C., Matthay K. K., Newman M. S., et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1105: 193
   PubMed Web of Science ®Google Scholar
• Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta 1990; 1029: 91
   PubMed Web of Science ®Google Scholar
• Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991; 1062: 77
   PubMed Web of Science ®Google Scholar
• Lasic D. D., Martin F. J., Gabizon A., Huang S. K., Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys Acta 1991; 1070: 187
   PubMed Web of Science ®Google Scholar
• Chonn A., Cullis P. R. Ganglioside GM1 and hydrophilic polymers increase liposome circulation times by inhibiting the association of blood proteins. J. Liposome Res. 1992; 2: 397
   Google Scholar
• Blume G., Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta 1993; 1146: 157
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A.J.M., Lokerse A. F., Ten Kate M. T., Storm G. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta 1992; 1138: 318
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A.J.M., Lokerse A. F., Ten Kate M. T., Mouton J. W., Woodle M. C., Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae, – infected lung tissue. J. Infect. Dis. 1993; 168: 164
   PubMed Web of Science ®Google Scholar
• Allen T. M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1991; 1068: 133
   PubMed Web of Science ®Google Scholar